Aadi bioscience announces publication of long-term efficacy and safety data further supporting fyarro® for the treatment of malignant pecoma

After 3 years of follow-up in ampect trial, confirmed clinically meaningful overall response rate, including multiple patients with complete responses demonstrated 40 months median duration of response and median survival >53 months historically, median survival has ranged from 16 to 29 months in the setting of metastatic/unresectable malignant pecoma1,2 los angeles , march 1, 2024 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mtor-driven cancers, announced today that long-term efficacy and safety results from its completed phase 2 registrational ampect study of nab-sirolimus in malignant pecoma were published in the journal of clinical oncology (jco). the manuscript, "a phase 2 trial of nab-sirolimus in patients with advanced malignant perivascular epithelioid cell tumors (ampect): long-term efficacy and safety update," authored by andrew j.
AADI Ratings Summary
AADI Quant Ranking